Literature DB >> 25049255

Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients.

Silvia Gómez-Zorrilla1, Mariana Camoez2, Fe Tubau2, Elisabet Periche3, Rosario Cañizares3, M Angeles Dominguez2, Javier Ariza1, Carmen Peña4.   

Abstract

The intestinal reservoir is central to the epidemiology of Pseudomonas aeruginosa, but the dynamics of intestinal colonization by different phenotypes have been poorly described. To determine the impact of antimicrobial exposure on intestinal colonization by multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa, we screened intensive care unit (ICU) patients for rectal colonization on admission and at weekly intervals. During an 18-month study period, 414 ICU patients were enrolled, of whom 179 (43%) were colonized; 112 (63%) of these were identified at ICU admission and 67 (37%) during their ICU stay. At 10 days after ICU admission, the probabilities of carriage were 44%, 24%, and 24% for non-MDR, MDR-non-XDR, and XDR P. aeruginosa strains, respectively (log rank, 0.02). Pulsed-field gel electrophoresis showed 10 pairs of non-MDR P. aeruginosa and subsequent MDR-non-XDR strains isolated from the same patients to be clonally identical and another 13 pairs (8 MDR-non-XDR and 5 XDR) to be unrelated. There was one specific clone between the 8 MDR-non-XDR strains and an identical genotype in the 5 XDR isolates. The Cox regression analysis identified MDR P. aeruginosa acquisition as associated with the underlying disease severity (adjusted hazard ratio [aHR], 1.97; 95% confidence interval [CI], 1.22 to 3.18; P = 0.006) and prior use of fluoroquinolones (aHR, 1.02; 95% CI, 1.00 to 1.04; P = 0.039), group 2 carbapenems (aHR, 1.03; 95% CI, 1.00 to 1.07; P = 0.041), and ertapenem (aHR, 1.08; 95% CI, 1.02 to 1.14; P = 0.004). The epidemiology of MDR P. aeruginosa is complex, and different clusters may coexist. Interestingly, ertapenem was found to be associated with the emergence of MDR isolates.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25049255      PMCID: PMC4187938          DOI: 10.1128/AAC.03419-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

2.  Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.

Authors:  Paul P Cook; Michael Gooch; Shemra Rizzo
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 3.  Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.

Authors:  David P Nicolau; Yehuda Carmeli; Christopher W Crank; Debra A Goff; Christopher J Graber; Ana Lucia L Lima; Ellie J C Goldstein
Journal:  Int J Antimicrob Agents       Date:  2011-11-01       Impact factor: 5.283

4.  The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.

Authors:  Yehuda Carmeli; Shiri Klarfeld Lidji; Esther Shabtai; Shiri Navon-Venezia; Mitchell J Schwaber
Journal:  Diagn Microbiol Infect Dis       Date:  2011-07       Impact factor: 2.803

5.  Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.

Authors:  A Deplano; O Denis; L Poirel; D Hocquet; C Nonhoff; B Byl; P Nordmann; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

6.  Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms.

Authors:  Didier Lepelletier; Anne Cady; Nathalie Caroff; Julie Marraillac; Alain Reynaud; Jean-Christophe Lucet; Stéphane Corvec
Journal:  Diagn Microbiol Infect Dis       Date:  2009-09-23       Impact factor: 2.803

7.  Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.

Authors:  C Peña; C Suarez; F Tubau; C Juan; B Moya; M A Dominguez; A Oliver; M Pujol; J Ariza
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

8.  Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.

Authors:  Gabriel Cabot; Alain A Ocampo-Sosa; M Angeles Domínguez; Juan F Gago; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-10-08       Impact factor: 5.191

9.  Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.

Authors:  C Peña; A Guzmán; C Suarez; M A Dominguez; F Tubau; M Pujol; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

10.  A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition.

Authors:  Cristina Suarez; Carmen Peña; Olga Arch; M Angeles Dominguez; Fe Tubau; Carlos Juan; Laura Gavaldá; Mercedes Sora; Antonio Oliver; Miquel Pujol; Javier Ariza
Journal:  BMC Infect Dis       Date:  2011-10-13       Impact factor: 3.090

View more
  17 in total

1.  Recent Anti-Microbial Exposure Is Associated with More Complications after Elective Surgery.

Authors:  Christopher A Guidry; Puja M Shah; Zachary C Dietch; Nathan R Elwood; Elizabeth D Krebs; J Hunter Mehaffey; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2018-06-08       Impact factor: 2.150

2.  Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa clinical infections.

Authors:  Silvia Gómez-Zorrilla; Mariana Camoez; Fe Tubau; Rosario Cañizares; Elisabet Periche; M Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

3.  Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.

Authors:  Silvia Gómez-Zorrilla; Francisco Morandeira; María José Castro; Fe Tubau; Elisabet Periche; Rosario Cañizares; María Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Microb Drug Resist       Date:  2016-10-18       Impact factor: 3.431

4.  Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure.

Authors:  Nazaret Cobos-Trigueros; Mar Solé; Pedro Castro; Jorge Luis Torres; Cristina Hernández; Mariano Rinaudo; Sara Fernández; Álex Soriano; José María Nicolás; Josep Mensa; Jordi Vila; José Antonio Martínez
Journal:  Crit Care       Date:  2015-05-04       Impact factor: 9.097

Review 5.  Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.

Authors:  Marion J Skalweit
Journal:  Drug Des Devel Ther       Date:  2015-06-04       Impact factor: 4.162

6.  Genome Sequence of a Pandrug-Resistant Pseudomonas aeruginosa Strain, YN-1.

Authors:  Hong-Li Tan; Yong Wang; Xue-Qin Cheng; Yan-Mei Huang; Wei Liu; Li-Juan Zhang
Journal:  Genome Announc       Date:  2014-12-24

7.  Prolonged outbreak of clonal MDR Pseudomonas aeruginosa on an intensive care unit: contaminated sinks and contamination of ultra-filtrate bags as possible route of transmission?

Authors:  Florian Salm; Maria Deja; Petra Gastmeier; Axel Kola; Sonja Hansen; Michael Behnke; Désirée Gruhl; Rasmus Leistner
Journal:  Antimicrob Resist Infect Control       Date:  2016-12-06       Impact factor: 4.887

8.  A prospective survey of Pseudomonas aeruginosa colonization and infection in the intensive care unit.

Authors:  Regev Cohen; Frida Babushkin; Shoshana Cohen; Marina Afraimov; Maurice Shapiro; Martina Uda; Efrat Khabra; Amos Adler; Ronen Ben Ami; Svetlana Paikin
Journal:  Antimicrob Resist Infect Control       Date:  2017-01-11       Impact factor: 4.887

9.  Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.

Authors:  Matthias Willmann; Anna M Klimek; Wichard Vogel; Jan Liese; Matthias Marschal; Ingo B Autenrieth; Silke Peter; Michael Buhl
Journal:  BMC Infect Dis       Date:  2014-12-10       Impact factor: 3.090

10.  Rates of gastrointestinal tract colonization of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa in hospitals in Saudi Arabia.

Authors:  B Abdalhamid; N Elhadi; N Alabdulqader; K Alsamman; R Aljindan
Journal:  New Microbes New Infect       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.